DE69942672D1 - Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns - Google Patents

Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Info

Publication number
DE69942672D1
DE69942672D1 DE69942672T DE69942672T DE69942672D1 DE 69942672 D1 DE69942672 D1 DE 69942672D1 DE 69942672 T DE69942672 T DE 69942672T DE 69942672 T DE69942672 T DE 69942672T DE 69942672 D1 DE69942672 D1 DE 69942672D1
Authority
DE
Germany
Prior art keywords
glucose utilization
nervous system
central nervous
agents
improvement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942672T
Other languages
English (en)
Inventor
Daniel G Chain
Mike Cawthorne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mindset Biopharmaceuticals (USA)
Original Assignee
Mindset Biopharmaceuticals (USA)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Biopharmaceuticals (USA) filed Critical Mindset Biopharmaceuticals (USA)
Application granted granted Critical
Publication of DE69942672D1 publication Critical patent/DE69942672D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F42—AMMUNITION; BLASTING
    • F42C—AMMUNITION FUZES; ARMING OR SAFETY MEANS THEREFOR
    • F42C15/00—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges
    • F42C15/24—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means
    • F42C15/26—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means using centrifugal force

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69942672T 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns Expired - Lifetime DE69942672D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11266998P 1998-12-17 1998-12-17
US12225899P 1999-02-24 1999-02-24
PCT/US1999/030066 WO2000035437A2 (en) 1998-12-17 1999-12-17 Improving mental performance by increasing brain insulin sensitivity

Publications (1)

Publication Number Publication Date
DE69942672D1 true DE69942672D1 (de) 2010-09-23

Family

ID=26810226

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942672T Expired - Lifetime DE69942672D1 (de) 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Country Status (8)

Country Link
EP (1) EP1140081B1 (de)
JP (1) JP2002532416A (de)
AT (1) ATE476978T1 (de)
AU (3) AU2192000A (de)
CA (1) CA2355645A1 (de)
DE (1) DE69942672D1 (de)
IL (2) IL143768A0 (de)
WO (1) WO2000035437A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
EP1454898A4 (de) 2001-12-13 2006-12-13 Ajinomoto Kk Neue phenylalaninderivate
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
CA2623204A1 (en) * 2005-09-22 2007-04-05 Sb Pharmco Puerto Rico Inc. Combination of rosiglitazone and donepezil for improvement of cognitive function
AU2008253134A1 (en) * 2007-05-24 2008-11-27 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Composition useful for the prevention of adverse effect due to the use of PPAR-gamma agonists
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
PL2582368T3 (pl) 2010-06-16 2018-08-31 Alfasigma S.P.A. Acetylo-karnityna do zastosowania w sposobie zwiększania neurogenezy w tkance nerwowej
JP6735224B2 (ja) 2016-01-28 2020-08-05 花王株式会社 アストロサイトのグルコース代謝活性化剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5039794A (en) * 1986-09-19 1991-08-13 Otsuka Pharmaceutical Co., Ltd. Tumor egress factor and processes for producing the same
IT1260155B (it) * 1992-08-03 1996-03-28 Fidia Spa Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
EP1124807A1 (de) * 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Heterocyclische verbindungen und ihre verwendung als arzneimittel, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
AU1887999A (en) * 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
PL341795A1 (en) * 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
JP2002527520A (ja) * 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び使用
JP2002527516A (ja) * 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
WO2000023416A1 (en) * 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527501A (ja) * 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、その製造及び利用
EP1123269A1 (de) * 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
US6028088A (en) * 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
CA2355645A1 (en) 2000-06-22
EP1140081B1 (de) 2010-08-11
AU2005201243A1 (en) 2005-04-21
WO2000035437A3 (en) 2000-11-09
AU2009200266A1 (en) 2009-02-19
JP2002532416A (ja) 2002-10-02
WO2000035437A2 (en) 2000-06-22
ATE476978T1 (de) 2010-08-15
IL143768A0 (en) 2002-04-21
IL143768A (en) 2008-04-13
AU2192000A (en) 2000-07-03
EP1140081A2 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
Milam et al. Local anesthetics in dental practice
Tarsy et al. Physostigmine in choreiform movement disorders
DE3687501D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
HUP0002373A2 (hu) Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
DE69519099D1 (de) Aromatische aminoether als schmerzlindernde mittel
DE69942672D1 (de) Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
IE41374B1 (en) A composition for treating schizophrenia
KR900007419A (ko) 1-[모노-또는 비스(트리플루오로메틸)-2-피리디닐]피페라진을 함유한 약학조성물
EP2481407B1 (de) Verbindungen zur Verwendung bei der Behandlung kognitiver Störungen
FI874865A (fi) Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
Wolkowicz et al. Dissociation between mitochondria calcium ion release and pyridine nucleotide oxidation.
GEP19981357B (en) New Adenozine Derivatives, Prepatation Methods and Pharmaceutical Composit¬i¬ons Containing Them
ES8602718A1 (es) Procedimiento para la preparacion de derivados de tiazolidina.
DE59209175D1 (de) Verwendung von prostacyclin-derivaten zur verhinderung oder behandlung von störungen der mikrozirkulation bei gabe von röntgen-, nmr- oder ultraschallkontrastmitteln
ATE182879T1 (de) Neuartig substituierte dtpa-derivate, deren metallkomplexe, diese komplexe enthaltende pharmazeutische mittel, deren verwendung in der diagnostik und therapie, sowie verfahren zur herstellung der komplexe und mittel
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
Davidoff et al. Enhancement of the mitochondrial Ca2+ uptake rate by phenethylbiguanide and other organic cations with hypoglycemic activity
Cotzias L-Dopa in Parkinson's disease
DE3778642D1 (de) Therapeutikum zur behandlung von magengeschwueren.
DE68918597T2 (de) Neues S-Timolol Derivat und Verfahren zu seiner Herstellung.
ATE71385T1 (de) Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.
FR2696743B1 (fr) Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
ATE28871T1 (de) Disubstituierte piperidine,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NO20001812D0 (no) Gallesyresalter av metaller med fysiologisk virkning, samt terapeutisk anvendelse derav